Drugs / HPIV3-EbovZ GP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02564575 | Aug 2015 → Nov 2016 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPIV3-EbovZ GP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02564575 ↗ |
| Modality | Vaccine | “HPIV3-EbovZ GP vaccine candidate” NCT02564575 ↗ |
| Route | Intranasal | “Administered intranasally by a VaxINator device” NCT02564575 ↗ |